Stock Alert: Shares of a company worth Rs 28,000 crore surged in a falling market, with FIIs and DIIs buying heavily.

News Topical, Digital Desk : Shares of the pharmaceutical company saw a significant rally on Monday. After opening near the previous close of ₹1,415.80, the stock rose sharply to cross ₹1,535. Over the past year, the stock has returned approximately 55% to investors. Significantly, foreign and domestic institutional investors are also steadily increasing their stakes in the company, strengthening market confidence in the stock.

Some pharmaceutical sector stocks saw significant activity on the stock market on Monday, with Emcure Pharmaceuticals Ltd. leading the pack.

The stock opened near the closing price of ₹1,415.80. However, after the market opened, buying increased rapidly, and the stock rose to over ₹1,535. Looking at its performance over the past year, Emcure's stock has proven to be a strong asset for investors, gaining nearly 55% during this period. A strong shareholding pattern is also considered a major reason for the company's rise. Emcure's promoters hold a 77.88% stake, which is considered a sign of investor confidence. Furthermore, institutional investor interest is also increasing. The share of foreign institutional investors (FIIs), which was 3.05% in December 2024, increased to 3.59% by December 2025. Not only foreign investors, but also domestic institutional investors (DIIs) have seen a sharp increase in their holdings. DII's stake increased from 3.87% in December 2024 to 6.1% by December 2025. This indicates that large investors have a positive outlook on the company's future. Regarding the company's business, Emcure Pharmaceuticals is one of India's leading pharmaceutical companies. The company develops, manufactures, and markets a variety of drugs. The company produces oral solids, injectable drugs, biotherapeutics, and active pharmaceutical ingredients (APIs). Emcure's drugs are used in several key medical segments.

In the gynecology segment, the company's drugs like Emprogest and Dydrofem are very popular. The company ranked number 1 in this segment in FY24.

In the cardiovascular segment, the company's portfolio includes drugs like Metpure, Eslo, and Rivaroxaban. Additionally, the company manufactures drugs like Pause and Vintor for the treatment of blood-related diseases.

The company is also active in the field of oncology, i.e., cancer-related drugs. Injectable products like Filgrastim and Oxaliplatin are part of its portfolio.

Additionally, the company manufactures anti-infective drugs, vitamin and mineral supplements like Zinconia and Bevon. The company also has a presence in HIV-related antiviral drugs.

Operationally, Emcure's business is spread across India as well as international markets. The company exports its products to over 70 countries. International markets account for approximately 51% of its total revenue.

The company has a strong presence in India and was the 13th largest pharmaceutical company in the country based on domestic sales in FY24.

The company's manufacturing facilities are located in Pune and Madhya Pradesh, producing everything from APIs to finished drugs, giving it the advantage of vertical integration.

The company is also continuously investing in research and development (R&D). In particular, the company's focus is increasing on chronic disease-related drugs and the biopharmaceutical segment.

Regarding financial performance, the company's revenue in FY24 was approximately ₹8,850 crore, while net profit (PAT) was approximately ₹895 crore.

Given the growing demand in the pharmaceutical sector and the company's strong product pipeline, many investors are keeping an eye on this stock.

Read More: Stock market crash: 'Will the stock market fall by -10%? This is where investors' opportunity lies.'